Stay updated on Regorafenib vs Fruquintinib in Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Regorafenib vs Fruquintinib in Colorectal Cancer Clinical Trial page.

Latest updates to the Regorafenib vs Fruquintinib in Colorectal Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2; removed the government-funding downtime notice and the previous Revision: v3.4.1.SummaryDifference0.5%

- Check21 days agoChange DetectedA site-wide notice regarding potential updates due to funding and a new revision stamp (Revision: v3.4.1) were added, replacing the previous v3.4.0. These changes do not affect study data, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page now displays a glossary and shows new versioning details: Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. The older labels Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.3%

- Check42 days agoChange DetectedRevision text updated from v3.3.3 to v3.3.4 in the page header.SummaryDifference0.1%

- Check64 days agoChange DetectedThe Locations section now lists Beijing Municipality as a separate location, replacing the previous combined Beijing Municipality Locations. Page revision updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.3%

- Check92 days agoChange DetectedThe page shows a minor revision update from v3.2.0 to v3.3.2 in the header/footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Regorafenib vs Fruquintinib in Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib vs Fruquintinib in Colorectal Cancer Clinical Trial page.